サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1751200

感染症体外診断の市場規模、シェア、動向分析レポート：製品別、技術別、用途別、検査部位別、地域別、セグメント予測、2025年～2030年

Infectious Disease In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Software), By Technology, By Application, By Test Location, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 190 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
感染症体外診断の市場規模、シェア、動向分析レポート：製品別、技術別、用途別、検査部位別、地域別、セグメント予測、2025年～2030年
出版日: 2025年05月22日
発行: Grand View Research
ページ情報: 英文 190 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

感染症体外診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の感染症体外診断の市場規模は、2025年から2030年にかけて2.54%のCAGRを記録し、2030年までに280億5,000万米ドルに達すると推定されています。

結核やCOVID-19などの感染症の有病率の上昇と技術の進歩が、今後数年間の製品需要を牽引すると予測されています。多剤耐性感染症の増加により、感染症の早期診断が強化されています。例えば、2021年のMicrobial Drug Resistance Journalによると、重症のSARS-CoV-2患者におけるMDR感染症の有病率は14%～50%でした。

感染診断前の診断と抗生物質による治療の遅れは、薬剤耐性菌の蔓延をさらにエスカレートさせ、業界の成長に有利な機会を生み出しています。業界では、消費者の需要に応えるため、数多くの製品が発売されています。例えば、2022年5月、BDは米国で感染症用自動診断プラットフォームを発表しました。このシステムは1700検体のローディングを可能にし、検体の選別の必要性も排除され、それによってエラーが減少します。様々な競合企業が提供する製品は、競争企業間の敵対関係を高めるために戦略的な価格設定がなされています。

しかし、感度と信念の違いにより、消費者がPoC検査とラボベースの検査のどちらかを選択しなければならない場合、購買行動の複雑さは顕著に増大します。業界は寡占的で、ホフマン・ラ・ロシュ社、アレール社、バイオメリュー社、BD社などがシェアの大半を占めています。世界の業界は価格に敏感で、費用対効果が高く効率的な製品を製造するという点で、プレーヤー間に厳しい競争が生じています。競争企業間の敵対関係は、新規バイオマーカーキットの発売が予想されることから、予測期間中に増加するとみられます。競合各社は、より高い市場シェアを獲得するため、製品の発売や認知度向上プログラムの実施など、重要な戦略を採用しています。

感染症体外診断市場レポートハイライト

  • 試薬製品セグメントは、検査での大量使用により、2024年に最大の収益シェアを占めました。
  • 用途別では、COVID-19分野が2024年に業界を支配しました。これは、ウイルスの蔓延を抑えるために検査への支出が多いためです。
  • 検査場所に基づくと、2024年には中央検査室セグメントが48.06％のシェアで支配的でした。これは、検査室ベースの検査の精度が高いため、PoCや家庭での検査に比べて信頼性が高く、これらの検査が他の2つのセグメントに対して競争優位性を持つためです。
  • 北米は、良好な規制の枠組み、予防・早期検査への注力、新規診断薬の採用率の高さから、2024年の世界産業で優位を占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 感染症体外診断市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 感染症体外診断市場分析ツール
    • ポーター分析
    • PESTEL分析

第4章 感染症体外診断市場：製品別推定・動向分析

  • セグメントダッシュボード
  • 感染症体外診断市場：製品別変動分析、2024年および2030年
  • 機器
    • MRSA
    • 連鎖球菌
    • クロストリジウム・ディフィシル
    • VRE
    • CRE
    • 呼吸器ウイルス
    • カンジダ
    • 結核と薬剤耐性結核
    • 胃腸パネル検査
    • クラミジア
    • 淋病
    • HPV
    • HIV
    • C型肝炎
    • B型肝炎
    • COVID-19
    • その他の感染症
  • 試薬
    • MRSA
    • 連鎖球菌
    • クロストリジウム・ディフィシル
    • VRE
    • CRE
    • 呼吸器ウイルス
    • カンジダ
    • 結核と薬剤耐性結核
    • 胃腸パネル検査
    • クラミジア
    • 淋病
    • HPV
    • HIV
    • C型肝炎
    • B型肝炎
    • COVID-19
    • その他の感染症
  • ソフトウェア
    • MRSA
    • 連鎖球菌
    • クロストリジウム・ディフィシル
    • VRE
    • CRE
    • 呼吸器ウイルス
    • カンジダ
    • 結核と薬剤耐性結核
    • 胃腸パネル検査
    • クラミジア
    • 淋病
    • HPV
    • HIV
    • C型肝炎
    • B型肝炎
    • COVID-19
    • その他の感染症

第5章 感染症体外診断市場：技術別推定・動向分析

  • セグメントダッシュボード
  • 感染症体外診断市場：技術別変動分析、2024年および2030年
  • 免疫測定
  • 分子診断
    • ポリメラーゼ連鎖反応（PCR）
    • インサイチューハイブリダイゼーション
    • 等温核酸増幅技術（INAAT）
    • チップとマイクロアレイ
    • シーケンシングとNGS
    • 転写媒介増幅
  • 微生物学
  • その他

第6章 感染症体外診断市場：用途別推定・動向分析

  • セグメントダッシュボード
  • 感染症体外診断市場：用途別変動分析、2024年および2030年
  • MRSA
  • 連鎖球菌
  • クロストリジウム・ディフィシル
  • VRE
  • CRE
  • 呼吸器ウイルス
  • カンジダ
  • 結核と薬剤耐性結核
  • 胃腸パネル検査
  • クラミジア
  • 淋病
  • HPV
  • HIV
  • C型肝炎
  • B型肝炎
  • COVID-19
  • その他の感染症
    • その他市場収益推計と予測、2018年-

第7章 感染症体外診断市場：検査部位別推定・動向分析

  • セグメントダッシュボード
  • 感染症体外診断市場：検査部位別変動分析、2024年および2030年
  • ポイントオブケア
  • 中央研究所
  • その他

第8章 感染症体外診断市場：地域別推定・動向分析

  • 感染症体外診断市場シェア（地域別、2024年および2030年）
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • デンマーク
    • ノルウェー
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東およびアフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ
    • クウェート

第9章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業分類
  • 企業の市場シェア分析
  • 企業ヒートマップ分析
  • 戦略マッピング
    • 拡大
    • 合併と買収
    • パートナーシップとコラボレーション
    • 新製品の発売
    • 研究開発
  • 企業プロファイル
    • QIAGEN
    • BD
    • bioMerieux SA
    • F. Hoffmann-La Roche, Ltd.
    • Hologic, Inc.（Gen Probe）
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers AG
    • Bio-Rad Laboratories, Inc.
    • Danaher
    • OraSure Technologies, Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global IVD Infectious Diseases Market, By Region, 2018 - 2030 (USD Billion)
  • Table 5 Global IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 6 Global IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 7 Global IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 8 Global IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 9 North America IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Billion)
  • Table 10 North America IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 11 North America IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 12 North America IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 13 North America IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 14 U.S. IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 15 U.S. IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 16 U.S. IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 17 U.S. IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 18 Canada IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 19 Canada IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 20 Canada IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 21 Canada IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 22 Mexico IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 23 Mexico IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 24 Mexico IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 25 Mexico IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 26 Europe IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Billion)
  • Table 27 Europe IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 28 Europe IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 29 Europe IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 30 Europe IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 31 U.K. IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 32 U.K. IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 33 U.K. IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 34 U.K. IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 35 Germany IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 36 Germany America IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 37 Germany America IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 38 Germany America IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 39 France IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 40 France IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 41 France IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 42 France IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 43 Spain IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 44 Spain IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 45 Spain IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 46 Spain IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 47 Italy IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 48 Italy IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 49 Italy IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 50 Italy IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 51 Denmark IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 52 Denmark IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 53 Denmark IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 54 Denmark IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 55 Sweden IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 56 Sweden IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 57 Sweden IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 58 Sweden IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 59 Norway IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 60 Norway IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 61 Norway IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 62 Norway IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 63 Asia Pacific IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Billion)
  • Table 64 Asia Pacific IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 65 Asia Pacific IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 66 Asia Pacific IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 67 Asia Pacific IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 68 China IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 69 China IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 70 China IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 71 China IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 72 Japan IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 73 Japan IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 74 Japan IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 75 Japan IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 76 India IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 77 India IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 78 India IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 79 India IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 80 South Korea IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 81 South Korea IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 82 South Korea IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 83 South Korea IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 84 Thailand IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 85 Thailand IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 86 Thailand IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 87 Thailand IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 88 Australia IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 89 Australia IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 90 Australia IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 91 Australia IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 92 Latin America IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Billion)
  • Table 93 Latin America IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 94 Latin America IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 95 Latin America IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 96 Latin America IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 97 Brazil IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 98 Brazil IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 99 Brazil IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 100 Brazil IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 101 Argentina IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 102 Argentina IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 103 Argentina IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 104 Argentina IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 105 MEA IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Billion)
  • Table 106 MEA IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 107 MEA IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 108 MEA IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 109 MEA IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 110 South Africa IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 111 South Africa IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 112 South Africa IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 113 South Africa IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 114 UAE IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 115 UAE IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 116 UAE IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 117 UAE IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 118 Saudi Arabia IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 119 Saudi Arabia IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 120 Saudi Arabia IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 121 Saudi Arabia IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 122 Kuwait IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 123 Kuwait IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 124 Kuwait IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 125 Kuwait IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)

List of Figures

  • Fig.1 IVD infectious diseases market segmentation
  • Fig.2 Market research process
  • Fig.3 Information procurement
  • Fig.4 Primary research pattern
  • Fig.5 Primary interviews in North America
  • Fig.6 Primary interviews in Europe
  • Fig.7 Primary interviews in Asia Pacific
  • Fig.8 Primary interviews in Middle East and Africa
  • Fig.9 Market research approaches
  • Fig.10 Value-chain-based sizing & forecasting
  • Fig.11 QFD modeling for market share assessment
  • Fig.12 Market formulation & validation
  • Fig.13 IVD infectious disease market snapshot
  • Fig.14 Segment Insights
  • Fig.15 Strategy framework
  • Fig.16 Penetration & growth prospect mapping
  • Fig.17 Consumer behavior analysis
  • Fig.18 Factors influencing North America IVD infectious diseases market (%)
  • Fig.19 Factors influencing Europe IVD infectious diseases market (%)
  • Fig.20 Factors influencing Asia Pacific IVD infectious diseases market (%)
  • Fig.21 Factors influencing Latin America IVD infectious diseases market (%)
  • Fig.22 Factors influencing Middle East and Africa IVD infectious diseases market (%)
  • Fig.23 Market driver relevance analysis (Current & future impact)
  • Fig.24 Global population growth, by age-group, 2012 - 2022 (Million)
  • Fig.25 Global percentage of population, by age group, 2000 and 2050
  • Fig.26 General trend of CLIA-waived tests
  • Fig.27 Market restraint relevance analysis (Current & future impact)
  • Fig.28 Porter's five forces analysis
  • Fig.29 PESTLE analysis
  • Fig.30 Strategy mapping
  • Fig.31 IVD infectious diseases market: Product movement analysis
  • Fig.32 Product segment dashboard
  • Fig.33 IVD infectious diseases market product outlook: Key takeaways
  • Fig.34 Instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.35 MRSA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.36 Streptococcus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.37 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.38 VRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.39 CRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.40 Respiratory virus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.41 Candida market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.42 TB & drug-resistant TB market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.43 GI panel testing market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.44 Chlamydia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.45 Gonorrhea market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.46 HPV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.47 HIV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.48 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.49 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.50 COVID-19 market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.51 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.52 Reagents market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.53 MRSA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.54 Streptococcus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.55 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.56 VRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.57 CRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.58 Respiratory virus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.59 Candida market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.60 TB & drug-resistant TB market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.61 GI panel testing market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.62 Chlamydia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.63 Gonorrhea market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.64 HPV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.65 HIV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.66 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.67 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.68 COVID-19 market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.69 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.70 Software market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.71 MRSA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.72 Streptococcus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.73 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.74 VRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.75 CRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.76 Respiratory virus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.77 Candida market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.78 TB & drug-resistant TB market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.79 GI panel testing market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.80 Chlamydia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.81 Gonorrhea market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.82 HPV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.83 HIV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.84 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.85 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.86 COVID-19 market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.87 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.88 IVD infectious diseases market: Technology movement analysis
  • Fig.89 Technology segment dashboard
  • Fig.90 IVD infectious diseases market technology outlook: Key takeaways
  • Fig.91 Immunoassay market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.92 Molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.93 PCR market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.94 In Situ Hybridization market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.95 INAAT market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.96 Chips and microarrays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.97 Sequencing & NGS market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.98 TMA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.99 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.100 Microbiology market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.101 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.102 IVD infectious diseases market: Technology movement analysis
  • Fig.103 Application segment dashboard
  • Fig.104 IVD infectious diseases market technology outlook: Key takeaways
  • Fig.105 MRSA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.106 Streptococcus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.107 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.108 VRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.109 CRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.110 Respiratory virus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.111 Candida market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.112 TB & drug-resistant TB market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.113 GI panel testing market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.114 Chlamydia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.115 Gonorrhea market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.116 HPV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.117 HIV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.118 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.119 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.120 COVID-19 market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.121 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.122 IVD infectious diseases market: Test location movement analysis
  • Fig.123 Test location segment dashboard
  • Fig.124 IVD infectious diseases market test location outlook: Key takeaways
  • Fig.125 Point of Care market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.126 Central laboratories market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.127 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.128 Regional outlook, 2023 & 2030
  • Fig.129 Regional market dashboard
  • Fig.130 Regional marketplace: Key takeaways
  • Fig.131 North America market share and leading players, 2023
  • Fig.132 Europe market share and leading players, 2023
  • Fig.133 Asia Pacific market share and leading players, 2023
  • Fig.134 Latin America market share and leading players, 2023
  • Fig.135 Middle East and Africa market share and leading players, 2023
  • Fig.136 North America, SWOT
  • Fig.137 Europe, SWOT
  • Fig.138 Asia Pacific, SWOT
  • Fig.139 Latin America, SWOT
  • Fig.140 Middle East and Africa, SWOT
  • Fig.141 North America IVD infectious diseases market, 2018 - 2030 (USD Billion)
  • Fig.142 U.S. key country dynamics
  • Fig.143 U.S. IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.144 Canada key country dynamics
  • Fig.145 Canada IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.146 Europe IVD infectious diseases market, 2018 - 2030 (USD Billion)
  • Fig.147 UK key country dynamics
  • Fig.148 UK IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.149 Germany key country dynamics
  • Fig.150 Germany IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.151 Spain key country dynamics
  • Fig.152 Spain IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.153 France key country dynamics
  • Fig.154 France IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.155 Italy key country dynamics
  • Fig.156 Italy IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.157 Denmark key country dynamics
  • Fig.158 Denmark IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.159 Sweden key country dynamics
  • Fig.160 Sweden IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.161 Norway key country dynamics
  • Fig.162 Norway IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.163 Asia Pacific IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.164 Japan key country dynamics
  • Fig.165 Japan IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.166 China key country dynamics
  • Fig.167 China IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.168 India key country dynamics
  • Fig.169 India IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.170 South Korea key country dynamics
  • Fig.171 South Korea IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.172 Australia key country dynamics
  • Fig.173 Australia IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.174 Thailand key country dynamics
  • Fig.175 Thailand IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.176 Latin America IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.177 Brazil key country dynamics
  • Fig.178 Brazil IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.179 Mexico key country dynamics
  • Fig.180 Mexico IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.181 Argentina key country dynamics
  • Fig.182 Argentina IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.183 MEA IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.184 South Africa key country dynamics
  • Fig.185 South Africa IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.186 Saudi Arabia key country dynamics
  • Fig.187 Saudi Arabia IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.188 UAE key country dynamics
  • Fig.189 UAE IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.190 Kuwait key country dynamics
  • Fig.191 Kuwait IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.192 Ansoff Matrix
  • Fig.193 Heat map analysis
  • Fig.194 Company market share analysis,2023
  • Fig.195 Company market position analysis
  • Fig.196 Market differentiators
目次
Product Code: 978-1-68038-716-2

Infectious Disease In Vitro Diagnostics Market Growth & Trends:

The global infectious disease in vitro diagnostics market size is estimated to reach USD 28.05 billion by 2030, registering a CAGR of 2.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases, such as tuberculosis & COVID-19, and technological advancements are projected to drive the product demand in the coming years. The rising prevalence of multi-drug resistant infections is enhancing the early diagnosis of infectious diseases. For instance, MDR infections are highly common in ICU patients, as per the Microbial Drug Resistance Journal in 2021, the prevalence of MDR infections in critically ill SARS-CoV-2 patients ranged between14% and 50%.

The delay in diagnosis and treatment with antibiotics before infection diagnosis is further escalating the prevalence of drug resistant-bacteria, creating a lucrative opportunity for industry growth. The industry is witnessing a significant number of product launches to meet the demands of consumers. For instance, in May 2022, BD introduced its automated diagnostic platform for infectious diseases in the U.S. The system allows the loading of 1700 specimens and the need for specimen sorting is also eliminated, thereby, reducing errors. Products offered by various competitors have been strategically priced to increase competitive rivalry.

However, complexity in buying behavior increases prominently when consumers have to choose between PoC and lab-based tests owing to differences in sensitivity and beliefs. The industry is oligopolistic with companies, such as Hoffmann-La Roche Ltd., Alere, bioMerieux, and BD, holding the majority of the share collectively. The global industry is price-sensitive, creating rigorous competition among players in terms of manufacturing cost-effective and efficient products. Competitive rivalry is estimated to increase during the forecast period owing to the expected launch of novel biomarker kits. Competitors are adopting key strategies, such as product launches and organizing awareness programs, to gain higher market shares.

Infectious Disease In Vitro Diagnostics Market Report Highlights:

  • The reagents product segment held the largest revenue share in 2024, owing to its high-volume usage in testing.
  • By application, the COVID-19 segment dominated the industry in 2024, due to the high expenditure on testing, to reduce the spread of the virus
  • Based on test location, the central laboratories segment dominated in 2024 with a share of 48.06%, due to the higher accuracy of laboratory-based tests, which makes them more reliable as compared to PoC and home tests, giving these tests a competitive edge over the other two segments
  • North America dominated the global industry in 2024, due to its favorable regulatory framework, focus on preventive & early testing, and the higher adoption rate of novel diagnostics in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Application
    • 1.2.4. Test Location
  • 1.3. Regional Scope
  • 1.4. Estimates and Forecast Timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
  • 1.7. Details of primary research
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity flow analysis (Model 1)
      • 1.9.1.1. Approach 1: Commodity flow approach
    • 1.9.2. Volume price analysis (Model 2)
      • 1.9.2.1. Approach 2: Volume price analysis
  • 1.10. Research Scope and Assumptions
    • 1.10.1. List of Secondary Sources
    • 1.10.2. List of Primary Sources
    • 1.10.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Infectious Disease In Vitro Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Growing geriatric population
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. High demand for PoC facilities
      • 3.2.1.4. Increasing prevalence of infectious diseases
      • 3.2.1.5. External funding for R&D activities
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. High prices of IVD tests
  • 3.3. Infectious Disease In Vitro Diagnostics Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Legal landscape

Chapter 4. Infectious Disease In Vitro Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Infectious Disease In Vitro Diagnostics Market: Product Movement Analysis, USD Billion, 2024 & 2030
  • 4.3. Instruments
    • 4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.2. MRSA
      • 4.3.2.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.3. Streptococcus
      • 4.3.3.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.4. Clostridium Difficile
      • 4.3.4.1. Clostridium Difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.5. VRE
      • 4.3.5.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.6. CRE
      • 4.3.6.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.7. Respiratory Virus
      • 4.3.7.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.8. Candida
      • 4.3.8.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.9. TB and Drug-resistant TB
      • 4.3.9.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.10. Gastro-intestinal Panel Testing
      • 4.3.10.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.11. Chlamydia
      • 4.3.11.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.12. Gonorrhea
      • 4.3.12.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.13. HPV
      • 4.3.13.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.14. HIV
      • 4.3.14.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.15. Hepatitis C
      • 4.3.15.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.16. Hepatitis B
      • 4.3.16.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.17. COVID-19
      • 4.3.17.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.18. Other Infectious Diseases
      • 4.3.18.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Reagents
    • 4.4.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.2. MRSA
      • 4.4.2.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.3. Streptococcus
      • 4.4.3.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.4. Clostridium Difficile
      • 4.4.4.1. Clostridium Difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.5. VRE
      • 4.4.5.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.6. CRE
      • 4.4.6.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.7. Respiratory Virus
      • 4.4.7.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.8. Candida
      • 4.4.8.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.9. TB and Drug-resistant TB
      • 4.4.9.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.10. Gastro-intestinal Panel Testing
      • 4.4.10.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.11. Chlamydia
      • 4.4.11.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.12. Gonorrhea
      • 4.4.12.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.13. HPV
      • 4.4.13.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.14. HIV
      • 4.4.14.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.15. Hepatitis C
      • 4.4.15.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.16. Hepatitis B
      • 4.4.16.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.17. COVID-19
      • 4.4.17.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.18. Other Infectious Diseases
      • 4.4.18.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Software
    • 4.5.1. Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.2. MRSA
      • 4.5.2.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.3. Streptococcus
      • 4.5.3.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.4. Clostridium Difficile
      • 4.5.4.1. Clostridium Difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.5. VRE
      • 4.5.5.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.6. CRE
      • 4.5.6.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.7. Respiratory Virus
      • 4.5.7.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.8. Candida
      • 4.5.8.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.9. TB and Drug-resistant TB
      • 4.5.9.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.10. Gastro-intestinal Panel Testing
      • 4.5.10.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.11. Chlamydia
      • 4.5.11.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.12. Gonorrhea
      • 4.5.12.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.13. HPV
      • 4.5.13.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.14. HIV
      • 4.5.14.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.15. Hepatitis C
      • 4.5.15.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.16. Hepatitis B
      • 4.5.16.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.17. COVID-19
      • 4.5.17.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.18. Other Infectious Diseases
      • 4.5.18.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Infectious Disease In Vitro Diagnostics Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Infectious Disease In Vitro Diagnostics Market: Technology Movement Analysis, USD Billion, 2024 & 2030
  • 5.3. Immunoassay
    • 5.3.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Molecular Diagnostics
    • 5.4.1. Molecular Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.2. Polymerase Chain Reaction (PCR)
      • 5.4.2.1. Polymerase Chain Reaction (PCR) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.3. In Situ Hybridization
      • 5.4.3.1. In Situ Hybridization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
      • 5.4.4.1. Isothermal Nucleic Acid Amplification Technology (INAAT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.5. Chips and Microarrays
      • 5.4.5.1. Chips and Microarrays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.6. Sequencing & NGS
      • 5.4.6.1. Sequencing & NGS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.7. Transcription Mediated Amplification
      • 5.4.7.1. Transcription Mediated Amplification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Microbiology
    • 5.5.1. Microbiology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Infectious Disease In Vitro Diagnostics Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Infectious Disease In Vitro Diagnostics Market: Application Movement Analysis, USD Billion, 2024 & 2030
  • 6.3. MRSA
    • 6.3.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Streptococcus
    • 6.4.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Clostridium difficile
    • 6.5.1. Clostridium difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. VRE
    • 6.6.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.7. CRE
    • 6.7.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.8. Respiratory Virus
    • 6.8.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.9. Candida
    • 6.9.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.10. TB and drug-resistant TB
    • 6.10.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.11. Gastro-intestinal panel testing
    • 6.11.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.12. Chlamydia
    • 6.12.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.13. Gonorrhea
    • 6.13.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.14. HPV
    • 6.14.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.15. HIV
    • 6.15.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.16. Hepatitis C
    • 6.16.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.17. Hepatitis B
    • 6.17.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.18. COVID-19
    • 6.18.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.19. Other Infectious Diseases
    • 6.19.1. Others Market Revenue Estimates and Forecasts, 2018 -

Chapter 7. Infectious Disease In Vitro Diagnostics Market: Test Location Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Infectious Disease In Vitro Diagnostics Market: Test Location Movement Analysis, USD Billion, 2024 & 2030
  • 7.3. Point of Care
    • 7.3.1. Point of Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Central Laboratories
    • 7.4.1. Central Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Others
    • 7.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Infectious Disease In Vitro Diagnostics Market: Regional Estimates & Trend Analysis

  • 8.1. Infectious Disease In Vitro Diagnostics Market Share, By Region, 2024 & 2030, USD Billion
  • 8.2. North America
    • 8.2.1. North America Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.2.2.3. Competitive Insights
      • 8.2.2.4. U.S. Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.2.3.3. Competitive Insights
      • 8.2.3.4. Canada Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Regulatory Landscape/Reimbursement Scenario
      • 8.2.4.3. Competitive Insights
      • 8.2.4.4. Mexico Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.2. U.K.
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.2.3. Competitive Insights
      • 8.3.2.4. U.K. Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.3.3. Competitive Insights
      • 8.3.3.4. Germany Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.4.3. Competitive Insights
      • 8.3.4.4. France Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.5.3. Competitive Insights
      • 8.3.5.4. Italy Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.6.3. Competitive Insights
      • 8.3.6.4. Spain Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.7. Sweden
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.7.3. Competitive Insights
      • 8.3.7.4. Sweden Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.8.3. Competitive Insights
      • 8.3.8.4. Denmark Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.9.3. Competitive Insights
      • 8.3.9.4. Norway Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.2. China
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. China Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Japan Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. India Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.5.3. Competitive Insights
      • 8.4.5.4. South Korea Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.6.3. Competitive Insights
      • 8.4.6.4. Australia Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.7.3. Competitive Insights
      • 8.4.7.4. Thailand Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. Brazil Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Argentina Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.2. Saudi Arabia
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Saudi Arabia Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.3. UAE
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. UAE Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.4. South Africa
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Landscape/Reimbursement Scenario
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. South Africa Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Landscape/Reimbursement Scenario
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. Kuwait Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Market Share Analysis
  • 9.4. Company Heat Map Analysis
  • 9.5. Strategy Mapping
    • 9.5.1. Expansion
    • 9.5.2. Mergers & Acquisition
    • 9.5.3. Partnerships & Collaborations
    • 9.5.4. New Product Launches
    • 9.5.5. Research And Development
  • 9.6. Company Profiles
    • 9.6.1. QIAGEN
      • 9.6.1.1. Participant's Overview
      • 9.6.1.2. Financial Performance
      • 9.6.1.3. Product Benchmarking
      • 9.6.1.4. Recent Developments
    • 9.6.2. BD
      • 9.6.2.1. Participant's Overview
      • 9.6.2.2. Financial Performance
      • 9.6.2.3. Product Benchmarking
      • 9.6.2.4. Recent Developments
    • 9.6.3. bioMerieux SA
      • 9.6.3.1. Participant's Overview
      • 9.6.3.2. Financial Performance
      • 9.6.3.3. Product Benchmarking
      • 9.6.3.4. Recent Developments
    • 9.6.4. F. Hoffmann-La Roche, Ltd.
      • 9.6.4.1. Participant's Overview
      • 9.6.4.2. Financial Performance
      • 9.6.4.3. Product Benchmarking
      • 9.6.4.4. Recent Developments
    • 9.6.5. Hologic, Inc. (Gen Probe)
      • 9.6.5.1. Participant's Overview
      • 9.6.5.2. Financial Performance
      • 9.6.5.3. Product Benchmarking
      • 9.6.5.4. Recent Developments
    • 9.6.6. Abbott
      • 9.6.6.1. Participant's Overview
      • 9.6.6.2. Financial Performance
      • 9.6.6.3. Product Benchmarking
      • 9.6.6.4. Recent Developments
    • 9.6.7. Quidel Corporation
      • 9.6.7.1. Participant's Overview
      • 9.6.7.2. Financial Performance
      • 9.6.7.3. Product Benchmarking
      • 9.6.7.4. Recent Developments
    • 9.6.8. Siemens Healthineers AG
      • 9.6.8.1. Participant's Overview
      • 9.6.8.2. Financial Performance
      • 9.6.8.3. Product Benchmarking
      • 9.6.8.4. Recent Developments
    • 9.6.9. Bio-Rad Laboratories, Inc.
      • 9.6.9.1. Participant's Overview
      • 9.6.9.2. Financial Performance
      • 9.6.9.3. Product Benchmarking
      • 9.6.9.4. Recent Developments
    • 9.6.10. Danaher
      • 9.6.10.1. Participant's Overview
      • 9.6.10.2. Financial Performance
      • 9.6.10.3. Product Benchmarking
      • 9.6.10.4. Recent Developments
    • 9.6.11. OraSure Technologies, Inc.
      • 9.6.11.1. Participant's Overview
      • 9.6.11.2. Financial Performance
      • 9.6.11.3. Product Benchmarking
      • 9.6.11.4. Recent Developments